Novel Approaches to Multiple Myeloma Therapy

Saturday, October 27, 2012
12:15 pm – 1:45 pm
Starlight Ballroom, Waldorf=Astoria

Chair:
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California

Continuing Medical Education
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex®, LLC designates this live educational activity for a maximum 1.5 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is specifically designed for community oncologists, hematologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with mantle-cell lymphoma.

Objectives
Upon successful completion of this educational activity, participants will be able to:
• Review the role of transplantation in salvage therapy for myeloma
• Assess current data on novel agents and how they might be combined or sequenced to treat relapsed/refractory myeloma
• Evaluate the utility of maintenance therapy after salvage treatment
• Use risk stratification, age, comorbidities, and other factors to guide treatment decisions for relapsed/refractory myeloma
• Balance treatment goals with minimization of toxicity in myeloma patients

Scientific Agenda

12:15 pm Lunch

12:20 pm Welcome and pre-activity case assessment via Audience Response System
James R. Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, California and Morton Coleman, MD, Center for Lymphoma and Myeloma, Weill Cornell Medical College, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York

12:25 pm Novel combination therapies for untreated disease
Andrzej J. Jakubowiak, MD, PhD, University of Chicago Medical Center, Chicago, Illinois

12:45 pm Treatment of relapsed/refractory disease with already approved drugs
James R. Berenson, MD

1:05 pm Novel agents: Promising results from recent clinical trials
Tomer Mark, MD, Center for Lymphoma and Myeloma Weill Cornell Medical College, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York

1:25 pm Post-activity audience case assessment via Audience Response System
Morton Coleman, MD

1:30 pm Expert roundtable discussion
James R. Berenson, MD, and Morton Coleman, MD

1:45 pm Take-home message and adjourn
James Berenson, MD

Registration
This is a complimentary educational activity for attendees of Lymphoma & Myeloma 2012. There is no cost to attend this activity or to obtain CME credits.

Support
The following companies have provided an educational grant in support of this symposium:

Organizer
Imedex®, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Web: www.imedex.com